Stock 2496 WUHAN YZY BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Wuhan YZY Biopharma Co., Ltd.

Equities

2496

CNE1000063C4

Delayed Hong Kong S.E.
Other stock markets
 04:08:22 2024-06-20 EDT 		5-day change 1st Jan Change
8.37 HKD -0.12% Intraday chart for Wuhan YZY Biopharma Co., Ltd. +11.90% -5.96%
05-24 Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference MT
05-24 Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference
MT
Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting
CI
Wuhan YZY Biopharma Co., Ltd. Announces the First Patient Enrolled in Phase III Clinical Trial of M701
CI
Wuhan YZY Biopharma Co., Ltd. Announces the First Patient Has Recently Been Enrolled in A Phase Ii Clinical Trial of M701
CI
Wuhan YZY Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
China Evergrande Debt Troubles Drag Hong Kong Stocks; Wuhan YZY Biopharma Closes Flat, LC Logistics Slip in Debut
MT
Wuhan YZY Biopharma Raises HK$121 Million in Hong Kong IPO, Prices at Bottom of Range
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2496 Stock
  4. News Wuhan YZY Biopharma Co., Ltd.
  5. Highlights